Clinical Trial Update: MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating FOLFOX alone or with AMG 102 or panitumumab as first-line treatment for advanced gastroesophageal adenocarcinoma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Adenocarcinoma
• Stomach Cancer

Drugs mentioned

• AMG 102 (AMG 102)
• FOLFOX
• Panitumumab (panitumumab)

Snippet

Sponsor: UNICANCER | Conditions: Malignant Neoplasm of Esophagus, Malignant Neoplasm of Stomach | Phase 2 | Status: COMPLETED